Skip to content

TheraSphere Y90 Glass Microspheres 5.5 GBq (US Commercial) OTT-SPE-FP-700 (990700.SPE)Recalls & reported problems

Biocompatibles Uk Ltd · TheraSphere Yttrium-90 Glass Microspheres 5.5 GBq Dose (US Commercial) · Class 3 · Implant

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05060116921427), received between Feb 27, 2026 and Feb 27, 2026 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 1 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Unintended Radiation Exposure1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryFeb 27, 2026Adverse Event Without Identified Device or Use Problem

    IT WAS REPORTED THAT MISADMINISTRATION OCCURRED, REQUIRING PRESCRIPTION MEDICATION. A 5.5 GBQ DOSE VIAL OF THERASPHERE MICROSPHERES WAS ORDERED TO TREAT THE LIVER. PRIOR TO THERASPHERE ADMINISTRATION, THE PATIENT UNDERWENT PRE-EMPTIVE EMBOLIZATION OF THE GASTRODUODENAL ARTERY (GDA) AND RIGHT GASTRIC ARTERY. FOLLOWING THERASPHERE ADMINISTRATION TO THE LEFT HEPATIC LOBE, IMAGING REVEALED A FOCUS OF ACTIVITY OVER THE LESSER CURVATURE OF THE STOMACH. THE PATIENT WAS STARTED ON A PROTON PUMP INHIBITOR (2X PER DAY) AND SUCRALFATE WITH PLANS FOR AN ESOPHAGOGASTRODUODENOSCOPY (EGD) IN 2-3 WEEKS. THERE WERE NO FURTHER PATIENT COMPLICATIONS AS A RESULT OF THIS EVENT.

    Patient problems: Unintended Radiation Exposure

    MAUDE report 24469160 ↗

Other Microspheres Radionuclide devices

All Microspheres Radionuclide devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page